Analysts expect Nabriva Therapeutics PLC – (NASDAQ:NBRV) to announce $980,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Nabriva Therapeutics’ earnings, with estimates ranging from $500,000.00 to $1.86 million. Nabriva Therapeutics reported sales of $460,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 113%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Nabriva Therapeutics will report full-year sales of $8.15 million for the current financial year, with estimates ranging from $3.38 million to $20.74 million. For the next fiscal year, analysts forecast that the business will report sales of $32.94 million, with estimates ranging from $18.77 million to $61.96 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.04. Nabriva Therapeutics had a negative return on equity of 139.52% and a negative net margin of 3,602.24%. The business had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.88 million.
Shares of NASDAQ:NBRV traded up $0.12 during trading on Thursday, reaching $2.28. 2,676,400 shares of the stock were exchanged, compared to its average volume of 720,186. The company has a debt-to-equity ratio of 0.56, a quick ratio of 5.55 and a current ratio of 5.67. Nabriva Therapeutics has a 12-month low of $1.12 and a 12-month high of $3.27. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -1.40 and a beta of 2.40. The firm’s 50-day moving average price is $2.36 and its 200 day moving average price is $2.39.
Several hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC raised its position in shares of Nabriva Therapeutics by 30.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 15,000 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $29,000. Two Sigma Advisers LP acquired a new stake in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $37,000. Parametric Portfolio Associates LLC raised its position in shares of Nabriva Therapeutics by 180.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 33,656 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Nabriva Therapeutics during the 2nd quarter valued at approximately $90,000. 3.02% of the stock is currently owned by institutional investors and hedge funds.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Further Reading: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.